Short sellers trimmed positions by 13% over the past month as GM heads into Tuesday's earnings call. Options sentiment sits near neutral while analysts hold a $94 mean target.
Short interest stands at 19.8 million shares as of April 23, representing 2.12% of the free float. That's down 0.3% over the past week and down 13.2% over the past month. Days to cover sits at 3.31 based on the latest FINRA data. Cost to borrow rose 28% week-over-week to 0.42%, though it remains modest in absolute terms. Utilisation holds at 0.39%, well below the 52-week high of 3.4%. The pullback in short interest suggests bears have reduced exposure heading into the print.
The put/call ratio closed at 0.77 on April 24, slightly above the 20-day mean of 0.76. The z-score of 0.96 indicates near-neutral sentiment. PCR sits in the middle of its 52-week range of 0.72 to 1.10. No unusual skew.
Analysts surveyed hold a mean price target of $94.15, though consensus rating and coverage counts are unavailable. Recent activity has been mixed. Goldman Sachs cut its target to $91 from $104 on April 14, maintaining Buy. UBS raised to $105 from $102 the same day, also maintaining Buy. Deutsche Bank upgraded to Buy from Hold and lifted its target to $90 from $83. Earlier, Wolfe Research upgraded to Outperform from Peer Perform on March 25, announcing a $96 target. RBC Capital raised to $107 in late January following the prior quarter's print. Benzinga's bull case points to GM regaining US market share leadership at 17.4% in 2025 and a $4 billion investment in domestic production. The bear case flags ongoing Cruise execution challenges and strategic pivots following a 2023 accident.
GM trades at a P/E of 6.13, up 2% over the past month. EV/EBITDA sits at 7.18, down 6% over 30 days. The stock ranks in the 67th percentile on 90-day EPS momentum and the 83rd percentile on forward EPS growth. Analyst recommendation divergence ranks in the 97th percentile, signaling a wide spread of views.
Insiders sold $91.5 million net over the past 90 days, led by President Mark Reuss. Most sales occurred in mid-February at prices near $80–$84. Vanguard holds 11.99% of shares, adding 76,000 in Q1. BlackRock owns 9.36%, up 188,000. FMR LLC increased its stake by 5.1 million shares to 1.36%.
GM last reported on January 27, 2026. Prior prints occurred in October and July 2025.
No ORTEX Alpha signals are currently active.
See the live data behind this article on ORTEX.
Open GM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
